Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Melanoma
100%
Tumor
39%
Gut Microbiota
37%
Microbiome
29%
Immune Checkpoint Blockade
27%
BRAF Inhibitor (BRAFi)
22%
Metastatic Melanoma
21%
Immune Checkpoint Inhibitors
20%
Cancer Immunotherapy
20%
Melanoma Patients
19%
T Cells
19%
Targeted Therapy
19%
Neoadjuvant
19%
Melanoma Cells
17%
Tumor Microenvironment
16%
Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4)
13%
In Cancer
13%
Mitogen-activated Protein Kinase
12%
Anti-programmed Cell Death Protein 1 (anti-PD-1)
12%
Tumor Immunity
12%
Immune Response
12%
Programmed Cell Death Protein 1 (PD-1)
11%
Nivolumab
11%
Tumor Cells
11%
Melanoma Treatment
11%
Neoadjuvant Therapy
11%
Immune Checkpoint Therapy
10%
Resistance Mechanism
10%
Programmed Death-ligand 1 (PD-L1)
10%
Cancer Treatment
10%
BRAF V600E
10%
Overall Survival
9%
BRAF Inhibition
9%
Clinical Outcomes
9%
Ipilimumab
8%
Immune Infiltration
8%
Pathological Response
8%
Microbes
7%
Fecal Microbiota Transplantation
7%
Therapeutic Response
7%
High Risk
7%
Response Rate
7%
Checkpoint Blockade
7%
Tumor-infiltrating Lymphocytes
7%
MEK Inhibitor (MEKi)
6%
BRAF-mutant Melanoma
6%
Clinical Trials
6%
Pancreatic Cancer
6%
Vemurafenib
6%
Cancer Types
6%
Medicine and Dentistry
Melanoma
69%
Malignant Neoplasm
26%
Immunotherapy
24%
Neoplasm
22%
Immune Checkpoint Blockade
21%
Metastatic Melanoma
19%
Targeted Therapy
17%
Diseases
15%
Tumor
13%
Microbiome
11%
T Cell
10%
Immune Checkpoint Inhibitor
9%
extracellular signal regulated kinase
9%
Cancer
8%
Neoadjuvant Therapy
8%
Gut Microbiome
7%
Clinical Trial
7%
Gut
7%
Biological Marker
7%
Overall Survival
7%
Systemic Therapy
6%
Treatment Response
6%
Cancer Therapy
5%
Pancreas Adenocarcinoma
5%
Lymph Node
5%
Connective Tissue Cancer
5%
Carcinogenesis
5%
Nivolumab
5%
Tumor Microenvironment
5%
Immunology and Microbiology
Immunotherapy
39%
Microbiome
33%
T Cell
31%
Immune Checkpoint Blockade
21%
Gut Microbiome
20%
Cancer Immunotherapy
17%
Immune Checkpoint Inhibitor
15%
Intestine Flora
12%
Immune Response
12%
Tumor Cell
11%
Cytotoxic T-Cell
10%
Lung
10%
Programmed Death-Ligand 1
10%
T Cell Receptor
10%
Microflora
9%
Tumor Immunity
8%
CTLA-4
8%
Bacterium
7%
Feces microflora
7%
B Cell
7%
CD8
7%
Overall Survival
6%
Immunocompetent Cell
6%
Nivolumab
6%
Immune Microenvironment
5%